Cervical Intraepithelial Neoplasia Clinical Trial
Official title:
Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel "Prime and Pull" Strategy
This is a randomized Phase II, three arm control trial in patients with Cervical Intraepithelial Neoplasia (CIN) 2/3 high grade cervical dysplasia. Patients with CIN 2/3 meeting eligibility criteria will have cervical biopsy specimens centrally reviewed by study pathologist to confirm diagnosis. HPV DNA test and HPV 16/18 genotyping will be performed from endocervical cytobrush samples to determine HPV status associated with the dysplasia. Patients who have CIN 2/3 with HPV+ disease will be enrolled in this study. Patients will be randomized to one of three arms: observation only (control), imiquimod only, imiquimod + 9-valent HPV vaccine.
The primary objectives of this study are as follows: - To determine treatment efficacy defined as histologic regression to CIN 1 or less at weeks 20-24 (4 to 8 weeks after the end of imiquimod treatment) in the HPV Vaccine + Imiquimod group compared to control, - To determine treatment efficacy defined as histologic regression to CIN 1 or less at weeks 20-24 (4 to 8 weeks after the end of imiquimod treatment) in the Imiquimod group compared to control. The secondary objectives of this study are as follows: - To assess complete regression (i.e., histologic remission) at weeks 20-24 (4 to 8 weeks after the end of imiquimod treatment) in each group, - To assess HPV clearance in each group, - To assess treatment tolerability. In addition to the primary and secondary objectives of this study, there additional exploratory/correlative objectives. The exploratory/correlative objectives are as follows: - To assess T cell infiltration in post-treatment cervical biopsies and endocervical cytobrush samples, - To assess HPV16 E7 immunity in CD4/CD8 T cells. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Completed |
NCT02907333 -
Testing Use of Condoms on Regression of Cervical Intraepithelial Neoplasia
|
N/A | |
Recruiting |
NCT02576262 -
HPV Integration Testing for Human Papillomavirus-Positive Women
|
N/A | |
Completed |
NCT01029990 -
Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program
|
Phase 0 | |
Recruiting |
NCT05078528 -
Low-cost Imaging Technology for Global Prevention of Cervical Cancer
|
N/A | |
Recruiting |
NCT05502367 -
A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia
|
Phase 1/Phase 2 | |
Completed |
NCT02494310 -
HRME: Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings
|
N/A | |
Active, not recruiting |
NCT03429582 -
Comparison of Cervical CIN II/III Treatment Outcomes With Thermal Ablation Device
|
N/A | |
Active, not recruiting |
NCT02140021 -
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
|
N/A | |
Not yet recruiting |
NCT05510830 -
Diagnostic Cervical Conization for Persistent Infection or Integration of HPV
|
N/A | |
Completed |
NCT02237326 -
Visual Inspection With Acetic Acid Compared to Lugol's Iodine in HIV-infected Women
|
N/A | |
Completed |
NCT00316706 -
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
|
Phase 3 | |
Withdrawn |
NCT03143491 -
Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)
|
Phase 2 | |
Completed |
NCT03293628 -
Comparing Two Techniques of Haemostasis After Cervical Conization
|
Phase 2 | |
Recruiting |
NCT05266898 -
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
|
Phase 4 | |
Completed |
NCT02481414 -
A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions
|
Phase 2 | |
Completed |
NCT02247999 -
Improving Cervical Cancer Screening Among HIV-Infected Women in India
|
||
Recruiting |
NCT04646954 -
DNA Methylation Testing for the Screening of Uterine Cervical Lesion
|
Phase 3 | |
Recruiting |
NCT04650711 -
Immunohistochemical Staining of p16 for the Screening of Cervical Cancer
|
Phase 2 | |
Completed |
NCT01544478 -
V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)
|
Phase 4 |